

Online Supplementary Material

Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung Cancer. *JHEOR*. 2025;12(2):98-107. [doi:10.36469/jheor.2025.142771](https://doi.org/10.36469/jheor.2025.142771)

List of Guideline-Recommended Treatments for Advanced Non-Small Cell Lung Cancer


Figure S1: Sample Selection

This supplementary material has been provided by the authors to give readers additional information about their work.



List of Guideline-Recommended Treatments for Advanced Non-Small Cell Lung Cancer

Adagrasib	Gefitinib
Ado-trastuzumab emtansine	Gemcitabine
Afatinib	Ipilimumab
Alectinib	Larotrectinib
Amivantamab-vmjw	Lorlatinib
Atezolizumab	Mobocertinib
Bevacizumab	Nivolumab
Brigatinib	Osimertinib
Cabozantinib	Paclitaxel
Capmatinib	Pembrolizumab
Carboplatin	Pemetrexed
Cemiplimab	Pralsetinib
Ceritinib	Ramucirumab
Cisplatin	Selpercatinib
Crizotinib	Sotorasib
Dacomitinib	Tepotinib
Dabrafenib	Trametinib
Docetaxel	Tremelimumab-actl
Durvalumab	Vemurafenib
Erlotinib	Vinorelbine
Entrectinib	
Fam-trastuzumab deruxtecan-nxki	

Figure S1. Sample Selection

Abbreviations: 1L, first line; EGFRm, epidermal growth factor receptor mutations; Ex19del, exon 19 deletions; FDA, Food and Drug Administration; ICD-9/10-CM, *International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification*; L858R, exon 21 L858R substitutions; LC, lung cancer; (N)SCLC, (non-) small cell lung cancer.

Notes:

^aDiagnoses for LC were identified based on the following ICD-9-CM codes: 162.2x-162.9x and ICD-10-CM codes: C34.x.

^bDiagnoses for metastatic cancer were identified based on ICD-9-CM codes: 196.x, 197.x, 198.x, 209.7 and ICD-10-CM codes: C77.x, C78.x, C79.x, C7B.x.

^cAntineoplastic treatments used to treat SCLC included: etoposide, irinotecan, and topotecan; LC-related surgeries included lung lobectomy, lung resection, segmentectomy, and pneumonectomy.